The Effect of Moderate- and High-Fat Meals on the Bioavailability of Dolutegravir/Rilpivirine Fixed-Dose Combination Tablet

Dolutegravir 50 mg (DTG) and rilpivirine 25 mg (RPV) are a newly approved 2-drug regimen for the treatment of HIV in virally suppressed patients. A 2-part study evaluated the relative bioavailability and food effect of five experimental fixed-dose combination (FDC) tablet formulations of DTG/RPV. Wh...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clin Pharmacol
Egile Nagusiak: Mehta, Rashmi, Piscitelli, Joseph, Wolstenholme, Allen, Fu, Caifeng, Crauwels, Herta, Wynne, Brian, Adkison, Kimberly
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Dove 2020
Gaiak:
Short Report
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7292371/
https://ncbi.nlm.nih.gov/pubmed/32607002
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CPAA.S250751
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak